Current Portfolio

Flagship invests in three principle business sectors: Therapeutics; Health Technologies; and Sustainability. Initial investments range between $250 thousand and $5 million, and we may invest up to $12-15 million during the life of a company. Click on a tab below to filter the listing of the portfolio by industry sector, or on a column heading to sort.

Company Description Status Initial Datesort icon
<a href="/venture-capital/all-companies/ensemble-therapeutics-corporation">Ensemble Therapeutics Corporation</a> Discovering and developing novel small molecule therapies for cancer and other serious diseases. Private 2004 View Profile
<a href="/venture-capital/all-companies/agios-pharmaceuticals-inc">Agios Pharmaceuticals, Inc.</a> Discovering and developing novel drugs to treat cancer and inborn errors of metabolism. Public 2007 View Profile
<a href="/venture-capital/all-companies/selecta-biosciences-inc">Selecta Biosciences, Inc.</a> Developing novel drugs that use immune modulating nanomedicines to generate targeted antigen-specific immune responses to prevent and treat disease. Private 2008 View Profile
<a href="/venture-capital/all-companies/visterra-inc">Visterra, Inc.</a> Discovering and developing innovative products that will transform the prevention and treatment of infectious diseases. Private 2008 View Profile
<a href="/venture-capital/all-companies/taris-biomedical-inc">TARIS Biomedical, Inc.</a> Developing novel treatments for urologic diseases. Private 2008 View Profile
<a href="/venture-capital/all-companies/axcella-health">Axcella Health</a> Pioneering revolutionary new medicines with a focus on amino acid homeostasis. Private 2010 View Profile
<a href="/venture-capital/all-companies/moderna">Moderna</a> Pioneering messenger RNA Therapeutics™, an entirely new in vivo drug modality. Private 2010 View Profile
<a href="/venture-capital/all-companies/tarveda-therapeutics-inc">Tarveda Therapeutics Inc.</a> Tarveda develops Pentarins™, which are novel miniaturized biologic drug conjugates uniquely designed to target, penetrate and treat solid tumors. Private 2012 View Profile
<a href="/venture-capital/all-companies/seres-therapeutics">Seres Therapeutics</a> Developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. Public 2012 View Profile
<a href="/venture-capital/all-companies/syros-pharmaceuticals-0">Syros Pharmaceuticals</a> Harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Private 2012 View Profile
<a href="/venture-capital/all-companies/editas-medicine">Editas Medicine</a> Leading genome editing company translating its proprietary technology into novel solutions to treat a broad range of genetically-driven diseases. Public 2013 View Profile
<a href="/venture-capital/all-companies/rubius-therapeutics">Rubius Therapeutics</a> Pioneering a new therapeutic modality using genetically modified red blood cells to create Red-Cell Therapeutics™ with the potential to treat diverse areas of high unmet medical need. Private 2014 View Profile
<a href="/venture-capital/all-companies/denali-therapeutics">Denali Therapeutics</a> Discovering and developing therapies for patients with neurodegenerative diseases. Private 2015 View Profile
<a href="/venture-capital/all-companies/evelo-biosciences">Evelo Biosciences</a> Transforming cancer therapy through a deep understanding of the cancer microbiome. Private 2015 View Profile
<a href="/venture-capital/all-companies/codiak-biosciences">Codiak BioSciences</a> Leading developer of exosome-based diagnostics and therapeutics. Private 2015 View Profile
<a href="/venture-capital/all-companies/kaleido-biosciences">Kaleido BioSciences</a> Private 2015 View Profile
<a href="/venture-capital/all-companies/cadena-bio">Cadena Bio</a> Cadena Bio is developing revolutionary ingredients that feed and nourish the human microbiome. Private 2016 View Profile